PSA Screening

The European ERSPC trial — the field's best evidence — shows PSA screening reduces prostate cancer mortality by roughly 20% in relative terms, which at 16 years of follow-up translates to inviting around 570 men and diagnosing an extra 18 to prevent one prostate cancer death. The parallel US trial (PLCO) found no benefit, but is now understood as nearly uninterpretable because most control-arm men got PSA tests anyway. So the honest summary is: a real mortality benefit, purchased at a steep ratio of diagnoses to deaths averted, with no demonstrated effect on all-cause mortality — numbers that support neither the test's evangelists nor its abolitionists, and explain why every major guideline landed on shared decision-making rather than a recommendation.

The UK ProtecT trial randomised men with screen-detected localised prostate cancer to surgery, radiotherapy or active monitoring, and its 15-year results reframed the disease: prostate-cancer-specific survival was around 97% in all three arms — treatment reduced metastasis and progression but did not change survival, while surgery and radiation carried their well-known tolls of incontinence and sexual dysfunction. For the low- and intermediate-risk cancers screening mostly finds, the trial says the diagnosis is rarely a death sentence on any pathway, time to decide is real, and aggressive treatment purchases less than patients assume. It is the single most decision-changing piece of evidence a newly diagnosed man can read.

PSA screening built the textbook overdiagnosis case: estimates run from 20% to half of screen-detected cancers being tumours that would never have caused harm, drawn from the autopsy reservoir in which over a third of elderly men carry the disease. Two reforms have genuinely improved the ratio. MRI-first pathways — scan before biopsy, biopsy only suspicious lesions — cut detection of clinically insignificant cancer by around half in the pivotal trials while maintaining detection of significant disease. And active surveillance converted diagnosis from treatment trigger to monitoring trigger: it is now the guideline-preferred and majority management for low-risk disease in several countries, meaning an overdiagnosed man's main injury can be limited to the label and the follow-up schedule rather than incontinence.

After swinging from enthusiasm (1990s mass screening) to rejection (the 2012 US grade D) and back to the middle, guidance has converged: the USPSTF assigns ages 55-69 a grade C — offer the test through individualised discussion of benefits and harms — and recommends against routine screening at 70+; European guidance moves toward organised risk-adapted programmes precisely to replace the chaotic opportunistic testing that maximises harm; and higher-risk groups (family history, Black men, BRCA2 carriers) merit earlier, more deliberate discussion, being underrepresented in the trials while carrying higher disease burden. The one universally condemned pattern is also the most common one: reflex PSA tests in elderly men ordered without any conversation at all.

The modern sequence bears little resemblance to the 1990s conveyor belt. A deliberate decision to test, ideally around 50-55 (earlier with risk factors); an abnormal result confirmed and contextualised — PSA rises with age, prostate volume, infection and recent ejaculation, and risk calculators or reflex markers can triage borderline values; MRI before any biopsy; targeted rather than blind sampling; genomic classifiers refining risk where results would change management; and for low-risk findings, active surveillance as the default with defined triggers for treatment. Each step exists to keep insignificant disease undiagnosed or untreated. Research pathways (Stockholm3, ongoing UK screening trials) are testing whether an organised version of this sequence finally makes population screening cleanly net-positive.

For men deciding about testing: the benefit is real and modest — on trial numbers, hundreds screened per death averted — and the main risk is being pulled into diagnosis and treatment of disease that needed neither; the decision legitimately goes either way, and deserves five minutes of actual discussion. For men with an elevated PSA: no biopsy before MRI, absent unusual circumstances. For men diagnosed with low-risk cancer: active surveillance is not doing nothing — it is the guideline-preferred management with excellent long-term outcomes, and ProtecT says the survival difference from immediate aggressive treatment is negligible. And for every reader: any clinic advertising PSA screening with survival percentages has told you it is selling, not informing.